January 29, 2026 a 04:38 pm
JNJ: Analysts Ratings - Johnson & Johnson
Johnson & Johnson, a leader in the healthcare sector, has refocused its strategy on its Innovative Medicine and MedTech segments after spinning off its Consumer Health division in 2023. As it targets higher growth and innovation, recent months have seen varying analyst views, reflecting both opportunity in its advanced tech solutions and challenges of competitive healthcare markets.
Historical Stock Grades
Analysis of the latest data suggests a slightly optimistic stance among analysts for JNJ. As of January 2026, there are 5 Strong Buy, 9 Buy, 11 Hold, 0 Sell, and 1 Strong Sell recommendations. The distribution of these ratings shows a mixed but positive sentiment, with notable confidence in the company's growth trajectory in the healthcare technology market.
| Rating Category | Count | Score Representation |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 9 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over the past months, the sentiment has shown slight shifts, reflecting changing market conditions and new strategic directions by JNJ. Noteworthy points include:
- An increase in the number of Strong Buy ratings since September 2025, suggesting growing optimism among analysts about JNJ's strategic focus.
- A stable count of Hold recommendations, which may signify cautious optimism, reflecting analysts' wait-and-see approach as JNJ evolves.
- Overall, analyst scrutiny of JNJ remains high, indicating consistent interest and valuation assessment changes in response to its strategic maneuvers.
Percentage Trends
Analyzing the percentage distribution of ratings over the months yields insights into shifting analyst confidence:
- The percentage of Strong Buy ratings has increased from 8% in July 2025 to approximately 15% in January 2026, indicating improved confidence in future growth prospects.
- Hold recommendations stabilized around 30-35%, reflecting a steady analytical perspective on the stock's performance potential.
- The absence of Sell ratings in recent months highlights decreased concerns about the downside risks, potentially signifying strengthened market confidence in JNJ.
Latest Analyst Recommendations
Recent analyst recommendations reveal both maintenance of previous ratings and selective upgrades, underscoring varied perspectives on JNJ's potential:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-28 | Overweight | Equal Weight | Morgan Stanley |
| 2026-01-27 | Hold | Hold | Freedom Capital Markets |
| 2026-01-23 | Buy | Buy | Guggenheim |
| 2026-01-22 | Overweight | Overweight | Wells Fargo |
| 2026-01-22 | Hold | Hold | Stifel |
Analyst Recommendations with Change of Opinion
Significant shifts in analyst opinions could indicate perceived changes in JNJ's risk or growth potential:
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-28 | Overweight | Equal Weight | Morgan Stanley |
| 2025-10-22 | Hold | Buy | Freedom Capital Markets |
| 2025-10-03 | Overweight | Equal Weight | Wells Fargo |
| 2025-09-23 | Buy | Neutral | Guggenheim |
| 2025-05-13 | Market Perform | Outperform | Leerink Partners |
Interpretation
The current analyst trends for Johnson & Johnson highlight a cautiously optimistic stance, with upgrades signaling confidence in its strategic pivot towards innovative medicine and medical technology. The stability in Hold ratings indicates a balanced view of risk and reward, reflective of current market conditions. Some indications of an optimistic market sentiment are present, but it is tempered by uncertainties inherent in the healthcare sector. Overall, the consensus remains cautiously positive, underpinned by JNJ’s solid reputation and strategic redirection.
Conclusion
In summary, Johnson & Johnson maintains a stable analyst position with a slightly positive outlook owing to its strategic business refocus and expansion into growth segments. Analysts' recommendations highlight both opportunities and risks ahead, with an observable trend towards greater optimism, reflected in recent upgrades. However, the healthcare sector's complexities and competition necessitate continued vigilance. For investors, JNJ's standing as a diversified healthcare leader presents both strategic opportunity and the need for prudent risk assessment. Maintaining a close watch on future strategic developments will be key to realizing potential benefits.